BofA Merrill Lynch, William Blair, Canaccord Genuity, SunTrust assist
By Devika Patel
Knoxville, Tenn., Oct. 3 – Vital Therapies, Inc. said it priced a $35 million public sale of stock with a $5.25 million greenshoe. The deal was announced Sept. 22.
The company will sell 2 million common shares at $17.50 per share. The price per share is a 2.89% discount to the Oct. 2 closing share price of $18.02.
BofA Merrill Lynch is the bookrunning manager.
Proceeds will be used for clinical development of the ELAD System, working capital and other general corporate purposes.
The biotherapeutics company is based in San Diego.
| Issuer: | Vital Therapies, Inc.
|
| Issue: | Common stock
|
| Amount: | $35 million
|
| Greenshoe: | $5.25 million
|
| Shares: | 2 million
|
| Price: | $17.50
|
| Warrants: | No
|
| Bookrunner: | BofA Merrill Lynch
|
| Lead manager: | William Blair
|
| Co-managers: | Canaccord Genuity and SunTrust Robinson Humphrey Inc.
|
| Announcement date: | Sept. 22
|
| Pricing date: | Oct. 3
|
| Stock symbol: | Nasdaq: VTL
|
| Stock price: | $18.02 at close Oct. 2
|
| Market capitalization: | $358.53 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
